The tyrosine kinase inhibitor is indicated to treat selected subtypes of the disease in adults who have received prior chemotherapy for metastatic disease or who have progressed within 12 months of neo-adjuvant therapy.
Votrient is already licensed for the first-line treatment of adults with renal cell carcinoma (RCC) and for RCC patients who have received prior cytokine therapy for advanced disease.
The efficacy and safety of pazopanib in STS were assessed in a randomised, double-blind, placebo controlled, multicentre, phase III study (PALETTE) involving 369 patients with certain subtypes of advanced STS who had previously received chemotherapy.
Pazopanib 800mg once daily significantly increased median progression-free survival to 4.6 months, compared with 1.6 months for placebo (HR=0.31 [95% CI: 0.24–-0.40]; p<0.0001).
Adverse events identified in this advanced STS population that had not previously been seen in advanced RCC patients included venous thromboembolic events and pneumothorax.
View Votrient drug record
Further information: GSK